Form 4: Galera Therapeutics Director Acquires Series B Preferred Stock Following Nova Pharmaceuticals Merger

Michael Friedman, a director of Galera Therapeutics, acquired Series B Preferred Stock as a result of the merger with Nova Pharmaceuticals on December 30, 2024.

Summary

• On December 30, 2024, Galera Therapeutics completed a merger with Nova Pharmaceuticals.
• As a result of the merger, Michael Friedman, a director of Galera Therapeutics, acquired 8,326.269 shares of Series B Non-Voting Convertible Preferred Stock.
• These shares were acquired in exchange for shares of Nova Pharmaceuticals Common Stock, converted at a ratio of 177.9117.
• The Series B Preferred Stock is held by Equity Trust Company, Custodian FBO Michael Friedman Roth IRA.
• The conversion of the Series B Preferred Stock into Common Stock will be subject to stockholder approval, with a vote expected between twelve and eighteen months after the merger closing.
• Upon stockholder approval, each share of Series B Preferred Stock will be convertible into 1,000 shares of Common Stock.

Sentiment

Score: 7

Explanation: The document reflects a completed merger, which is generally a positive development. The acquisition of preferred stock by a director suggests confidence in the company's future. However, the conversion is subject to stockholder approval, introducing a degree of uncertainty.

Positives

• The merger between Galera Therapeutics and Nova Pharmaceuticals has been successfully completed.
• A director of Galera Therapeutics now holds a significant amount of Series B Preferred Stock, potentially aligning his interests with the company's success.

Risks

• The conversion of Series B Preferred Stock into Common Stock is contingent upon stockholder approval, which is not guaranteed.
• The timing of the stockholder vote is uncertain, occurring between twelve and eighteen months after the merger closing.

Future Outlook

The Issuer will submit to its stockholders for their consideration the approval of the conversion of the Series B Preferred Stock into shares of Common Stock no earlier than twelve months following the Closing, but no later than eighteen months following the Closing.

Industry Context

Mergers and acquisitions are common in the pharmaceutical industry as companies seek to expand their pipelines, acquire new technologies, or achieve synergies. This merger allows Galera Therapeutics to potentially strengthen its position in the market.

Comparison to Industry Standards

• The conversion ratio of 177.9117 for Nova Common Stock to Galera Series B Preferred Stock is specific to this transaction and its valuation.
• The future conversion of Series B Preferred Stock to Common Stock at a 1:1000 ratio is a fairly standard structure for preferred stock in similar deals.

Stakeholder Impact

• Shareholders will be impacted by the potential conversion of Series B Preferred Stock into Common Stock, which could dilute existing shares.
• The merger could impact employees of both Galera Therapeutics and Nova Pharmaceuticals, potentially leading to restructuring or integration efforts.

Next Steps

• Galera Therapeutics will seek stockholder approval for the conversion of Series B Preferred Stock into Common Stock between twelve and eighteen months after the closing date.

Key Dates

Keywords

Merger, Galera Therapeutics, Nova Pharmaceuticals, Series B Preferred Stock, Michael Friedman, Conversion, Stockholder Approval